XBiotech (Nasdaq:XBIT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

XBIT 주식 개요

바이오 제약 회사인 엑스바이오텍은 다양한 질병 치료를 위한 진정한 인간 단일 클론 항체를 발굴, 개발 및 상용화하는 기업입니다.

XBIT 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

보상

위험 분석

지난 5년간 매년 수익이 55.3% 씩 감소했습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동성

XBiotech Inc. 경쟁사

uniQure

NasdaqGS:QURE

US$247.4m

Solid Biosciences

NasdaqGS:SLDB

US$272.5m

Frequency Therapeutics

NasdaqCM:FREQ

US$547.3m

Altimmune

NasdaqGM:ALT

US$459.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 XBiotech
과거 주가
현재 주가	US$7.73
52주 최고치	US$9.96
52주 최저치	US$3.51
베타	1.4
11개월 변경	20.78%
3개월 변경 사항	35.85%
1년 변경 사항	100.78%
33년 변화	-40.49%
5년 변화	-14.68%
IPO 이후 변화	-65.96%

최근 뉴스 및 업데이트

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Aug 30

XBiotech: Several Shots On Goal In Big Target Market Indications

May 24

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

May 13

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Feb 09

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

주주 수익률

	XBIT	US Biotechs	US 마켓
7D	13.8%	-0.1%	0.8%
1Y	100.8%	21.7%	33.4%

수익률 대 산업: XBIT 지난 1년 동안 15.9 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: XBIT 지난 1년 동안 21.1 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is XBIT's price volatile compared to industry and market?
XBIT volatility
XBIT Average Weekly Movement	11.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: XBIT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: XBIT 의 주간 변동성( 12% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2005	94	John Simard	www.xbiotech.com

바이오 제약 회사인 엑스바이오텍은 다양한 질병 치료를 위한 진정한 인간 단일 클론 항체를 발굴, 개발 및 상용화하는 회사입니다. 이 회사는 염증성 질환과 감염성 질환을 표적으로 하는 제품 후보 파이프라인을 개발하는 데 주력하고 있습니다. 또한 암, 뇌졸중, 심장마비, 관절염 등 다양한 질환을 치료하고 조직 파괴, 혈관 신생, 혈전 형성, 불쾌감, 근육 소모, 염증을 매개하는 인터루킨-1 알파 치료제를 개발하고 있습니다.

XBiotech Inc. 기본 사항 요약

XBiotech 의 수익과 매출은 시가총액과 어떻게 비교하나요?
XBIT 기본 통계
시가총액	US$219.64m
수익(TTM)	-US$35.01m
수익(TTM)	n/a

0.0x

P/S 비율

-6.7x

P/E 비율

XBIT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
XBIT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$35.01m
수익	-US$35.01m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.15
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	5.1%

XBIT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

XBIT 주식 개요

보상

위험 분석

XBiotech Inc. 경쟁사

NasdaqGS:QURE

US$247.4m

NasdaqGS:SLDB

US$272.5m

NasdaqCM:FREQ

US$547.3m

NasdaqGM:ALT

US$459.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

주주 수익률

가격 변동성

회사 소개

XBiotech Inc. 기본 사항 요약

0.0x

-6.7x

수익 및 수익